A detailed history of Assenagon Asset Management S.A. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 170,234 shares of TGTX stock, worth $5.03 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
170,234
Previous 488,943 65.18%
Holding current value
$5.03 Million
Previous $8.7 Million 54.23%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$17.21 - $25.28 $5.48 Million - $8.06 Million
-318,709 Reduced 65.18%
170,234 $3.98 Million
Q2 2024

Jul 18, 2024

BUY
$13.32 - $19.19 $6.51 Million - $9.38 Million
488,943 New
488,943 $8.7 Million
Q3 2023

Nov 06, 2023

BUY
$8.36 - $26.5 $1.22 Million - $3.86 Million
145,846 New
145,846 $1.22 Million
Q1 2023

Apr 18, 2023

BUY
$10.23 - $19.34 $2.36 Million - $4.46 Million
230,602 New
230,602 $3.47 Million
Q2 2022

Jul 27, 2022

BUY
$3.74 - $10.66 $6.86 Million - $19.6 Million
1,834,924 Added 722.33%
2,088,952 $8.88 Million
Q1 2022

Apr 25, 2022

BUY
$7.81 - $20.45 $721,245 - $1.89 Million
92,349 Added 57.12%
254,028 $2.42 Million
Q4 2021

Feb 01, 2022

BUY
$15.2 - $35.51 $2.46 Million - $5.74 Million
161,679 New
161,679 $3.07 Million
Q3 2021

Oct 19, 2021

SELL
$21.78 - $40.45 $3.33 Million - $6.18 Million
-152,823 Closed
0 $0
Q2 2021

Jul 15, 2021

SELL
$32.5 - $48.96 $111,280 - $167,639
-3,424 Reduced 2.19%
152,823 $5.93 Million
Q1 2021

Apr 26, 2021

BUY
$41.61 - $54.3 $6.5 Million - $8.48 Million
156,247 New
156,247 $7.53 Million
Q1 2019

Apr 26, 2019

SELL
$4.02 - $8.04 $629,933 - $1.26 Million
-156,700 Closed
0 $0
Q4 2018

Jan 23, 2019

BUY
$3.44 - $5.76 $539,048 - $902,592
156,700 New
156,700 $642,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.